What are the limitations of the CARPREG II Cardiac Risk?

While the CARPREG II Cardiac Risk is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the CARPREG II Cardiac Risk to ensure safe bedside use and optimal diagnostic accuracy.

How does the CARPREG II Cardiac Risk compare to other Obstetrics scores?

The CARPREG II Cardiac Risk is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the CARPREG II Cardiac Risk free to use?

Yes. OpiCalc provides the CARPREG II Cardiac Risk completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

CARPREG II Cardiac Risk

CARPREG II Risk Score

Maternal Cardiac Risk Index

Calculated Cardiac Risk Score

0

Prob. Primary Cardiac Event

Primary cardiac events include: heart failure, sustained arrhythmia, stroke, myocardial infarction, or cardiac death.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

Predicting the risk of primary maternal cardiac complications during pregnancy
Risk stratification for women with pre-existing congenital or acquired heart disease, or arrhythmias
Pre-pregnancy counseling to establish realistic expectations regarding maternal morbidity

When NOT to Use

The CARPREG II score is designed to predict MATERNAL cardiac outcomes, not fetal or neonatal outcomes. Furthermore, it does not factor in obstetric risk factors (e.g., maternal age, extreme obesity, or preeclampsia risk) which can independently exacerbate cardiac reserve.

CLINICAL INSIGHT

How it Works

Scoring Variables

Prior cardiac event or arrhythmia

Baseline NYHA class III-IV or cyanosis

Mechanical heart valve

Systemic ventricular dysfunction (LVEF <55%)

High-risk left-sided valve disease / LVOT obstruction

Pulmonary hypertension (RVSP >49 mmHg)

Coronary artery disease

High-risk aortopathy

No prior cardiac intervention

Late pregnancy assessment (>20 weeks)

Risk of Primary Cardiac Event

0–1 Point

2 Points

3 Points

4 Points

≥ 5 Points

CLINICAL INSIGHT

Practical Pearls

Key Strengths

Outperforms the original CARPREG and ZAHARA indices in modern validation cohorts
Integrates process-of-care variables (like >20 weeks at first assessment) reflecting the reality of delayed antenatal care
Evaluated on a massive, contemporary dataset of high-risk obstetric conditions

Known Limitations

Derived largely in high-income tertiary care centers with expert multidisciplinary teams; actual risks in lower-resource settings may be significantly higher than predicted
May overestimate risk in the lowest-scoring brackets and slightly underestimate risk in some mid-range cohorts (like certain valvular diseases)

CLINICAL INSIGHT

Next Steps

High Risk (Score ≥ 4)

Immediate referral to a specialized multidisciplinary Cardio-Obstetric team
Early formulation of a highly detailed labor and delivery plan (including fluid management and precise anesthesia targets)
Deliver strictly at a tertiary care center equipped with adult cardiovascular ICU and ECMO capability
Consider early delivery if maternal hemodynamics deteriorate heavily in the late third trimester

Complementary Guidelines

Current expert consensus recommends utilizing CARPREG II alongside the modified WHO (mWHO) classification. While mWHO excels at identifying absolute contraindications to pregnancy (Class IV), CARPREG II offers superior, individualized statistical prediction of specific event rates.

CLINICAL INSIGHT

Evidence Base

Primary Derivation Reference

Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study.

Silversides CK, Grewal J, Mason J, et al.J Am Coll Cardiol.2018

CLINICAL INSIGHT

Background

The CARPREG Registry

The Cardiac Disease in Pregnancy (CARPREG) registry was established in Canada to track outcomes for pregnant women with structural, congenital, or arrhythmic heart disease. The CARPREG II update was necessary to adapt to modern medical advancements, incorporating deeper nuances like pulmonary hypertension and aortopathy that were missing from the pioneering original model.

CARPREG II Cardiac Risk

CARPREG II Risk Score

Maternal Cardiac Risk Index

Calculated Cardiac Risk Score

0

Prob. Primary Cardiac Event

Primary cardiac events include: heart failure, sustained arrhythmia, stroke, myocardial infarction, or cardiac death.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Clinical Uses

Predicting the risk of primary maternal cardiac complications during pregnancy
Risk stratification for women with pre-existing congenital or acquired heart disease, or arrhythmias
Pre-pregnancy counseling to establish realistic expectations regarding maternal morbidity

When NOT to Use

CLINICAL INSIGHT

How it Works

Scoring Variables

Prior cardiac event or arrhythmia

Baseline NYHA class III-IV or cyanosis

Mechanical heart valve

Systemic ventricular dysfunction (LVEF <55%)

High-risk left-sided valve disease / LVOT obstruction

Pulmonary hypertension (RVSP >49 mmHg)

Coronary artery disease

High-risk aortopathy

No prior cardiac intervention

Late pregnancy assessment (>20 weeks)

Risk of Primary Cardiac Event

0–1 Point

2 Points

3 Points

4 Points

≥ 5 Points

CLINICAL INSIGHT

Practical Pearls

Key Strengths

Outperforms the original CARPREG and ZAHARA indices in modern validation cohorts
Integrates process-of-care variables (like >20 weeks at first assessment) reflecting the reality of delayed antenatal care
Evaluated on a massive, contemporary dataset of high-risk obstetric conditions

Known Limitations

Derived largely in high-income tertiary care centers with expert multidisciplinary teams; actual risks in lower-resource settings may be significantly higher than predicted
May overestimate risk in the lowest-scoring brackets and slightly underestimate risk in some mid-range cohorts (like certain valvular diseases)

CLINICAL INSIGHT

Next Steps

High Risk (Score ≥ 4)

Immediate referral to a specialized multidisciplinary Cardio-Obstetric team
Early formulation of a highly detailed labor and delivery plan (including fluid management and precise anesthesia targets)
Deliver strictly at a tertiary care center equipped with adult cardiovascular ICU and ECMO capability
Consider early delivery if maternal hemodynamics deteriorate heavily in the late third trimester

Complementary Guidelines

CLINICAL INSIGHT

Evidence Base

Primary Derivation Reference

Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study.

Silversides CK, Grewal J, Mason J, et al.J Am Coll Cardiol.2018

CLINICAL INSIGHT